Drug Profile
Research programme: carbapenemase inhibitors - The Medicines Company
Alternative Names: RPX 7307; RPX 7381; RPX 7400Latest Information Update: 17 Jan 2020
Price :
$50
*
At a glance
- Originator The Medicines Company
- Class
- Mechanism of Action Beta lactamase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 06 Jan 2020 The Medicines Company has been acquired by Novartis
- 28 Oct 2019 No recent reports of development identified for preclinical development in Bacterial-infections in USA
- 15 Sep 2015 Preclinical trials in Bacterial infections in USA (unspecified route)